PROK
NASDAQ · Biotechnology
Prokidney Corp
$1.64
+0.00 (+0.00%)
Open$1.66
Previous Close$1.64
Day High$1.70
Day Low$1.62
52W High$3.48
52W Low$1.45
Volume—
Avg Volume808.7K
Market Cap495.38M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+1,108.5% upside
Current
$1.64
$1.64
Target
$19.82
$19.82
$13.43
$19.82 avg
$25.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.96M | 45.98M | 42.93M |
| Net Income | -150,958,323 | 9.61M | 10.78M |
| Profit Margin | -7,725.2% | 20.9% | 25.1% |
| EBITDA | -346,705,835 | 17.18M | 13.92M |
| Free Cash Flow | — | 13.69M | 9.06M |
| Rev Growth | — | +20.4% | +3.7% |
| Debt/Equity | 0.00 | 0.62 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |